VOR BIOPHARMA INC. - COMMON STOCK

Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

14 мар 2022 15:30:15 Источник Nasdaq GlobeNewswire

Vor to Participate in Three Upcoming Investor Conferences

28 фев 2022 07:00:02 Источник Nasdaq GlobeNewswire

Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

11 фев 2022 07:00:00 Источник Nasdaq GlobeNewswire

Vor to Participate in Two Upcoming Investor Conferences

04 янв 2022 07:00:02 Источник Nasdaq GlobeNewswire

Vor to Participate in the JMP Securities Hematology and Oncology Summit

29 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference

19 ноя 2021 15:01:00 Источник Nasdaq GlobeNewswire

Vor Reports Third Quarter 2021 Financial Results and Provides Company Update

10 ноя 2021 15:10:00 Источник Nasdaq GlobeNewswire

Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting

09 ноя 2021 07:30:00 Источник Nasdaq GlobeNewswire

Vor to Participate in Two Upcoming Investor Conferences

08 ноя 2021 07:00:02 Источник Nasdaq GlobeNewswire

Vor to Present New Platform and Preclinical Data at ASH

04 ноя 2021 08:15:00 Источник Nasdaq GlobeNewswire

Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT

19 окт 2021 06:00:01 Источник Nasdaq GlobeNewswire

Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management

12 окт 2021 07:00:02 Источник Nasdaq GlobeNewswire

VOR33 Granted U.S. FDA Fast Track Designation for AML

09 сен 2021 07:00:03 Источник Nasdaq GlobeNewswire

Vor to Participate in Three Upcoming Investor Conferences

02 сен 2021 07:00:00 Источник Nasdaq GlobeNewswire

Vor Reports Second Quarter 2021 Financial Results and Provides Company Update

09 авг 2021 15:05:01 Источник Nasdaq GlobeNewswire

Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

08 июл 2021 07:00:01 Источник Nasdaq GlobeNewswire

Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs

17 июн 2021 07:00:01 Источник Nasdaq GlobeNewswire

Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp

11 июн 2021 07:00:00 Источник Nasdaq GlobeNewswire

Vor to Develop Multi-Targeted CAR-Ts with Abound Bio

10 июн 2021 07:00:01 Источник Nasdaq GlobeNewswire

Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences

25 май 2021 15:10:00 Источник Nasdaq GlobeNewswire